Trial Profile
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel (G/NP) or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 10 Apr 2024
Price :
$35
*
At a glance
- Drugs Pamrevlumab (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Acronyms LAPIS
- Sponsors FibroGen
- 26 Feb 2024 According to a FibroGen media release, topline data from this LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic cancer (LAPC) expected in 2Q 2024.
- 20 Feb 2024 Planned End Date changed from 31 Dec 2023 to 30 Apr 2024.
- 20 Feb 2024 Planned primary completion date changed from 31 Dec 2023 to 30 Apr 2024.